Neurodon Corp.

About Science Pipeline Publications News Contact About Science Pipeline Publications News Contact About Science Pipeline Publications News Contact About Science Pipeline Publications News Contact Press Release Oct 24, 2024 Neurodon has recently become a Member of the Longevity Biotechnology Association, a global non-profit organization aimed at identifying aging pathways that can be targeted therapeutically to extend lifespan and health. Neurodon joins a group of leading biotech and pharmaceutical companies, investors, and researchers interested in investigating the primary drivers of aging and age-related diseases. There is a growing body of evidence that aberrant cellular calcium homeostasis, ER stress, and the UPR are correlated with aging and age-associated diseases such as neurodegeneration. Since Neurodon’s focus is on correcting this dysfunction, we envision leveraging our insight and small molecules to target aging both in a disease-focused and global manner. By partnering with the LBA, we will join like minded companies, researchers, and investors to generate new medicines to extend lifespan and improve health in the aging population. Read more about the LBA here. Read comments from the LBA about Neurodon joining here. About Science Pipeline FCOI policy About Science Pipeline FCOI policy Publications News Contact Publications News Contact

About Science Pipeline Publications News Contact About Science Pipeline Publications News Contact About Science Pipeline Publications News Contact About Science Pipeline Publications News Contact Press Release Oct 09, 2023 Neurodon, a pharmaceutical company focused on the discovery and development of novel therapies for neurodegeneration, diabetes, and rare disease, announced today that it has been awarded approximately $2.9 million in continued funding under its Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This grant will be used for continued development and Investigational New Drug (IND)-enabling studies to support clinical translation of the company’s small molecule activators of the SERCA enzyme for Alzheimer’s disease. Neurodon’s novel molecules have demonstrated neuroprotective properties and the ability to improve learning and memory in several preclinical models of Alzheimer’s disease. To date, the company has been awarded over $5 million in funding from the NIA for their Alzheimer’s disease therapeutic development program. “We are extremely grateful for the NIA’s continued support of our molecules targeting neuron loss in Alzheimer’s disease,” said Russell Dahl, Ph.D., Founder and CEO of Neurodon and the Principal Investigator of the grant. “This funding, which supports the completion of key studies required to submit an IND to the FDA and start clinical trials, is further validation that SERCA activation is a promising strategy for the development of disease-modifying agents for Alzheimer’s disease and has the potential to bring hope to patients and their loved ones.” As in their previously funded Alzheimer’s disease research, Neurodon will team up with scientists in the Purdue Animal Behavioral Core (PBAC) at the Purdue Institute for Integrative Neuroscience. Purdue University is a top public research institution with world-class research facilities and faculty. “All of us at the Purdue Institute for Integrative Neuroscience are grateful to have this opportunity to partner with Neurodon. Alzheimer’s disease is one of our institute’s strategic initiatives and we are glad to be a part of these efforts. We would like to thank the NIA for their tremendous support and to Neurodon for inviting us to be part of the team,” stated Wendy Koss, Ph.D., Director of the PBAC and Assistant Research Professor at Purdue University. “The NIA has been very supportive of our Alzheimer’s disease research, providing not only critical funding but also comprehensive resources for small business development,” added Colleen Mauger, R.N., Vice President of Operations at Neurodon. “This funding, in addition to investments we have recently received for other pipeline programs, further validates our platform and positions Neurodon well to be able to submit at least 2 IND applications to the FDA in the next 12-24 months.” About Science Pipeline FCOI policy About Science Pipeline FCOI policy Publications News Contact Publications News Contact

CROWN POINT, Ind., Oct. 3, 2023 /PRNewswire/ -- Neurodon, a pharmaceutical company focused on the discovery and development of novel therapies for neurodegeneration, diabetes, and rare disease, announced today that it has been awarded approximately $2.9 million in continued funding under its Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This grant will be used for continued development and Investigational New Drug (IND)-enabling studies to support clinical translation of the company's small molecule activators of the SERCA enzyme for Alzheimer's disease. Neurodon's novel molecules have demonstrated neuroprotective properties and the ability to improve learning and memory in several preclinical models of Alzheimer's disease. To date, the company has been awarded over $5 million in funding from the NIA for their Alzheimer's disease therapeutic development program. "We are extremely grateful for the NIA's continued support of our molecules targeting neuron loss in Alzheimer's disease," said Russell Dahl, Ph.D., Founder and CEO of Neurodon and the Principal Investigator of the grant. "This funding, which supports the completion of key studies required to submit an IND to the FDA and start clinical trials, is further validation that SERCA activation is a promising strategy for the development of disease-modifying agents for Alzheimer's disease and has the potential to bring hope to patients and their loved ones." As in their previously funded Alzheimer's disease research, Neurodon will team up with scientists in the Purdue Animal Behavioral Core (PBAC) at the Purdue Institute for Integrative Neuroscience. Purdue University is a top public research institution with world-class research facilities and faculty. "All of us at the Purdue Institute for Integrative Neuroscience are grateful to have this opportunity to partner with Neurodon. Alzheimer's disease is one of our institute's strategic initiatives and we are glad to be a part of these efforts. We would like to thank the NIA for their tremendous support and to Neurodon for inviting us to be part of the team," stated Wendy Koss, Ph.D., Director of the PBAC and Assistant Research Professor at Purdue University. "The NIA has been very supportive of our Alzheimer's disease research, providing not only critical funding but also comprehensive resources for small business development," added Colleen Mauger, R.N., Vice President of Operations at Neurodon. "This funding, in addition to investments we have recently received for other pipeline programs, further validates our platform and positions Neurodon well to be able to submit at least 2 IND applications to the FDA in the next 12-24 months." About Neurodon Neurodon is developing disease-modifying drugs for neurodegeneration, diabetes, and other life-threatening and rare diseases. Neurodon's patented molecules target fundamental pathways of cellular stress that are at the root cause of many devastating diseases. Neurodon deploys its proprietary platform technology to discover small molecule new chemical entities that correct cellular dysfunction and have demonstrated the ability to reverse the disease state in multiple preclinical models. For more information, visit . Contact: Colleen Mauger 219-225-2104 366268@email4pr.com